Watch CRNX. Know when insiders buy.
One email the day a filing lands. Free.
CRNX
Crinetics Pharmaceuticals, Inc.
No price history available
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
41
WATCH · shorts 41
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 1
buys / sells · latest disclosed Sep 4
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP —P/E —DIV YIELD —FCF YIELD —REV TTM $42.2M +2928.4%NET INCOME −$501.6MNET CASH —52W —SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $25.1M | +2336.3% | 99.4% | −$132.5M | −$120.9M | — | -1.14 | −$94.2M | $521K | −$94.7M | Aug 3 |
| Q1 2026 · Mar 31 | $10.7M | +2873.4% | 98.1% | −$140.4M | −$127.8M | — | -1.23 | −$124.7M | $820K | −$125.5M | May 7 |
| Q4 2025 · Dec 31derived | $6.2M | — | — | −$133.7M | −$122.8M | — | -1.29 | −$92.9M | $458K | −$93.4M | Feb 26 |
| Q3 2025 · Sep 30 | $143K | — | — | −$142.6M | −$130.1M | — | -1.38 | −$110.7M | $863K | −$111.6M | Nov 6 |
| Q2 2025 · Jun 30 | $1M | +158.4% | 100.0% | −$129.1M | −$115.6M | — | -1.23 | −$85.9M | $3.2M | −$89.1M | Aug 3 |
| Q1 2025 · Mar 31 | $361K | −43.6% | 100.0% | −$111.4M | −$96.8M | — | -1.04 | −$88.5M | $1.2M | −$89.7M | May 7 |
| Q4 2024 · Dec 31derived | $0 | — | — | −$94.7M | −$80.6M | — | -0.87 | −$66.9M | $1M | −$67.9M | Feb 26 |
| Q3 2024 · Sep 30 | $0 | −100.0% | — | −$87.8M | −$76.8M | — | -0.96 | −$62.8M | $528K | −$63.4M | Nov 6 |
| Q2 2024 · Jun 30 | $399K | — | — | −$82.8M | −$74.1M | — | -0.94 | −$47.6M | $955K | −$48.6M | Aug 7 |
| Q1 2024 · Mar 31 | $640K | — | — | −$73.5M | −$66.9M | — | -0.93 | −$52.9M | $1.3M | −$54.2M | May 8 |
| Q4 2023 · Dec 31derived | $0 | — | — | −$62.7M | −$60.1M | — | -0.88 | −$40.8M | $935K | −$41.7M | Feb 26 |
| Q3 2023 · Sep 30 | $346K | — | — | −$59M | −$57.5M | — | -1.01 | −$41.3M | $3.5M | −$44.8M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $7.7M | 86.0% | −$516.8M | −$465.3M | -6046.2% | -4.95 | −$377.9M | $5.8M | −$383.7M | — | — |
| FY2024 · to Dec 31 | $1M | 100.0% | −$338.9M | −$298.4M | -28720.7% | -3.69 | −$230.2M | $3.8M | −$234M | — | — |
| FY2023 · to Dec 31 | $4M | 100.0% | −$222.6M | −$214.5M | -5345.9% | -3.69 | −$168.6M | $4.7M | −$173.3M | — | — |
| FY2022 · to Dec 31 | $4.7M | — | −$167.9M | −$163.9M | -3460.4% | -3.15 | −$115.2M | $1.7M | −$116.9M | — | — |
| FY2021 · to Dec 31 | $1.1M | — | −$107.7M | −$107.6M | -9985.3% | -2.80 | −$88.6M | $436K | −$89M | — | — |
| FY2020 · to Dec 31 | $71K | — | −$75M | −$73.8M | -103960.6% | -2.42 | −$62M | $186K | −$62.2M | — | — |
Every number comes from Crinetics Pharmaceuticals, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.